Cascade
Latest round
- Series D
Last raised
- Jun 2026
Total raised
- $161M
Investors
- 17
About Cascade
, trading as Cascade, is a biomedical enterprise committed to innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs). In December 2021, CS0159 completed the first subject administration in the US. In September 2022, it completed clinical phase I administration in the US. The R&D team has accumulated more than 20 years of innovative drug research and development. The founder and CEO, Eric Xu, graduated from Duke University and served as a senior investigator at Glaxo Wellcome and GSK. The company focuses on innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs). It has established a Class 1 new drug pipeline and a dozen of drug candidates, of which the core product of a non-cholic acid drug molecule CS0159 targeting FXR has completed US clinical Phase 1, and Phase 2 will be initiated. It also developed the drug molecular design and synthesis platform, molecular cell analysis platform for in vitro efficacy and target verification, in vivo small animal efficacy evaluation platform. The company's revenue is generated by selling innovative drugs such as novel nucleic acid drugs and drugs targeting new mechanisms.
Who invested in Cascade
17 investors across 3 rounds
See all investors in Cascade
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Cascade
Who invested in Cascade?
Cascade has 17 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Cascade raised?
Cascade has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Cascade last raise money?
Cascade's most recent round on record is a Series D, in Jun 2026.
What does Cascade do?
, trading as Cascade, is a biomedical enterprise committed to innovative drugs targeting nuclear receptors and G protein-coupled receptors (GPCRs).
Where is Cascade headquartered?
Cascade is headquartered in Shanghai, China.
Which VCs invest in companies like Cascade?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Cascade's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Cascade? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.